SIX technological steps
to enhance your research
Innovation, the key to performance
Our solutions are the result of over a decade of expertise in functional genomics. The process we developed has been optimized to produce powerful, reliable results at close-to-physiological conditions.
CELLULAR MODEL
Extensive expertise in cellular biology and culture optimization in a wide range of cellular models.
3D High-Content Screening
Integrated and automated process for drug profiling on 3D tumor models.
The traditional method for studying cancer in vitro is to grow cancer cells in 2-D monolayers on plastic. Yet, tumor microenvironment is very complex and heterogeneous and the 2-D artificial conditions do not sufficiently mimic how the physiological tumor will react to a drug. Spheroids, self-assembled aggregates of cancer cells, are one of the most promising models. This model naturally mimics tumors, is simple to form and allows a reproducibility of the measured phenotypes (cell proliferation, cell viability…). The major challenges for the use of spheroids in high-throughput functional screening tend to have a visualization system specifically committed to 3-D structures and a robust and reliable data analysis. Here we present an innovative and powerful functional screening process dedicated to 3-D tumor models.
RESULTS
3 types of breast organoids were treated with Everolimus (2 concentrations 100 µM in red 10 µM in green).
Organoids were labeled with 2µM CellEvent Caspase 3/7 Green Detection (apoptosis).
Images were acquired after 48h of everolimus treatment.
A- Caspase 3/7 labeling ctrl
B- Composte – brightfield and Caspase 3/7
C- Caspase 3/7 labeling after Everolimus treatment (100 µM)
D- Composite after Everolimus treatment (100 µM)
We propose to analyse your compounds with the standard conditions belowed:
- 5 dilutions in triplicates.
- Treatment times upon request.
- 5 readouts included: area, apoptosis (Caspase 3/7 labeling), ATP assay (WST-1 based assay),
- cytotoxicity, growth inhibition.
- 4 packs: 6 – 24 – 48 and… more compounds or with your specific conditions.
- Several hundreds of 3D tumor models per well.
- Automatic analysis for different morphologies of 3D tumor models (grape-like, mass, round…)
- New robust statistical data processing dedicated to physiological models.
- Validate compound efficiency with more physiological tumor models.
- Use an integrated process from 3D cultures to data processing.
- Improve the reliability with our automated platform.
RNAI-based screening
List of provided siRNA libraries
All our libraires are tested with a 80% efficiency rate and are non-pooled siRNAs.
- 1. Genome-wide (human genes)
- 2. Cell death and stress response library (human genes)
- 3. Cancer library
- 4. Kinase library ((human genes)
- 5. LNA library: genome-wide (micro-ARN)
- 6. Phosphatase library
- 7. Nuclear Receptors Library
- 8. Customized library
METHOD
Functional screening of 7000 genes

Imaging system
(capacity of 20 000 phenotypic features)
- High-content analysis.
- Cells segmentation.
- Integrated analysis, visualisation software.
- Fluorescent and brightfield measurement.
(capacity of 1000 phenotypic features)
- True 3D image reconstitution.
- High resolution.
- High content imaging.
- Fluorescent and brightfield measurement.
Data analysis
Phi-score – a new cell-by-cell score
Innovative statistical data processing dedicated to High-content Screening using physiological cellular models. Cell function is influenced by parameters like genetic material and micro-environmental stimuli. Our aim is to conduct screening on cells (primary cells from healthy or tumor tissue) with a genetic background as close to actual physiological conditions as possible.
These physiological cellular models present technical contraints:
- Low transfection rates.
- Low number of cells or organoids.
- High-variability.
Phi-score 3 times less false positive
To overcome these challenges, we developed Phi-score. A robust statistical score, based on an individual fluorescence rank. This score takes into account:
- The number of cells or organoids per well.
- The number of wells per treatment.
- The response variability between wells.
Example: Validation of the Lapatinib (Tykerb, GSK) effect on HER2-positive breast cancer

in the challenging culture conditions of physiological models